Goldman Sachs analyst Corinne Johnson reiterated a Buy rating and $50.00 price target on Immunovant (NASDAQ: IMVT).The analyst comments "Yesterday ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE